Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | NPR1 | P16066 | 15/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168721 | 0.92 | NPR1 (0.48) | APPBCHEACHENPR1EGLN1 | |
| SCHEMBL4184947 | 0.90 | PDE5A (0.47) | NPR1EGLN1AVPR1B | |
| SCHEMBL4184720 | 0.90 | NSD2 (0.49) | NPR1TRIM58 | |
| SCHEMBL4182349 | 0.88 | LMNA (0.53) | NPR1EGLN1AVPR1B | |
| SCHEMBL4180714 | 0.86 | EGLN1 (0.44) | NPR1EGLN1AVPR1B | |
| SCHEMBL4186187 | 0.86 | NPR1 (0.45) | NPR1EGLN1AVPR1B | |
| SCHEMBL4184096 | 0.86 | NSD2 (0.46) | NPR1EGLN1AVPR1B | |
| SCHEMBL4173222 | 0.83 | NSD2 (0.49) | NPR1EGLN1AVPR1BKDM1AEHMT2 | |
| SCHEMBL4188225 | 0.83 | TLR7 (0.50) | NPR1EGLN1AVPR1B | |
| SCHEMBL4177505 | 0.83 | NPR1 (0.44) | NPR1EGLN1AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | claimed |
| EP-1996562-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104560-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-09-20 | — | — | WO | claimed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | APP 2173/4885BCHE 1821/4885ACHE 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.